Trial reportJournal of Korean medical science2010
Changes of antimicrobial peptides and transepidermal water loss after topical application of tacrolimus and ceramide-dominant emollient in patients with atopic dermatitis.
Trial report in Journal of Korean medical science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Pooled it
- Clinical use of a ceramide-based moisturizer for treating dogs with atopic dermatitis.Journal of veterinary science · 2013Trial
- Efficacy of Topical Application of a Skin Moisturizer Containing Pseudo-Ceramide and a Eucalyptus Leaf Extract on Atopic Dermatitis: A Review.Journal of clinical medicine · 2024Review
- Immunomodulatory Effects of the Pea Defensin Psd1 in the Caco-2/Immune Cells Co-Culture uponInternational journal of molecular sciences · 2023Article
- Skin barrier status during dupilumab treatment in patients with severe atopic dermatitis.Therapeutic advances in chronic disease · 2021Article
- Role of Antimicrobial Peptides in Skin Barrier Repair in Individuals with Atopic Dermatitis.International journal of molecular sciences · 2020Review
- Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis.Clinical, cosmetic and investigational dermatology · 2018Review
- Current insights into the role of human β-defensins in atopic dermatitis.Clinical and experimental immunology · 2017Review
- Lipid abnormalities and lipid-based repair strategies in atopic dermatitis.Biochimica et biophysica acta · 2014Review
- Topical corticosteroid application and the structural and functional integrity of the epidermal barrier.The Journal of clinical and aesthetic dermatology · 2013Article
- Lidocaine inhibits staphylococcal enterotoxin-stimulated activation of peripheral blood mononuclear cells from patients with atopic dermatitis.Archives of dermatological research · 2013Article
- Pathways to managing atopic dermatitis: consensus from the experts.The Journal of clinical and aesthetic dermatology · 2013Article
- Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients.Drugs in R&D · 2013Article
- An evaluation of barrier repair foam on the molecular concentration profiles of intrinsic skin constituents utilizing confocal Raman spectroscopy.The Journal of clinical and aesthetic dermatology · 2012Article
- The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation.Skin pharmacology and physiology · 2012Review
- Skin barrier function and its importance at the start of the atopic march.Journal of allergy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased transepidermal water loss (TEWL) and downregulated antimicrobial peptides (AMPs) are observed in patients with atopic dermatitis (AD). Tacrolimus and ceramide-dominant emollients are effective in the treatment of AD by preventing the production of inflammatory cytokines and by correcting skin barrier dysfunctions, respectively. Present study was designed to investigate the relationship between antimicrobial and barrier factors by measuring the changes of AMPs and TEWL after topical application of tacrolimus and ceramide-dominant emollient in the patients with AD. A total of three patients with AD were treated with tacrolimus in one lesion and ceramide-dominant emollient in another lesion for 4 weeks. RT-PCR and western blotting revealed that the mRNA and protein expression levels of hBD-2 and LL-37 were increased on the both study sites. Immunohistochemical analysis showed significant increase of AMPs and IL-1alpha, while, IL-4 was decreased on the both study sites. The mean changes of TEWL and AMPs showed no statistical difference between both sites. Tacrolimus and ceramide-dominant emollient influence on both TEWL and AMPs expression in patients with AD, namely they have similar effects on both of the two. This study shows that restoration of permeability barrier function is accompanied by the concomitant improvement of antimicrobial defense in patients with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.